Zenas BioPharma
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary inve...
Latest News
18 days ago · marketbeat.com
Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision NearsZenas BioPharma NASDAQ: ZBIO outlined development plans for obexelimab in systemic lupus erythematosus (SLE) and ZB021, an investigational oral IL-17AA/AF inhibitor, during an R&D event ahead of clinical data expected later in the quarter.
21 days ago · seekingalpha.com
Zenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development TranscriptZenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development Transcript
25 days ago · zacks.com
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should KnowThe mean of analysts' price targets for Zenas BioPharma, Inc. (ZBIO) points to a 77.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
1 month ago · globenewswire.com
Zenas BioPharma to Host Virtual R&D EventWALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host a virtual R&D event on Tuesday, October 27, 2026, from 8:00 – 9:30 a.m. ET.
1 month ago · seekingalpha.com
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong CurveZenas BioPharma (ZBIO) is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date, positioning as a long-term maintenance therapy. ZBIO maintains a sizable cash runway, with pro forma balances covering operations into late 2028, though financing risk remains if FDA approval is delayed. Obexelimab's non-depleting B cell inhibition offers a differentiated safety profile versus Uplizna, targeting chronic use in older patients and potentially expanding the addressable market.
2 months ago · seekingalpha.com
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease TranscriptZenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
2 months ago · seekingalpha.com
Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptZenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago · seekingalpha.com
Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptZenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
2 months ago · globenewswire.com
Zenas BioPharma to Host Obexelimab IgG4-RD Investor EventWALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 – 9:30 a.m. ET.
2 months ago · globenewswire.com
Zenas BioPharma to Present at Upcoming Healthcare Investor ConferencesWALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management's presentations at the following investor conferences: Citi Biopharma Back to School Conference on Wednesday, September 9, 2026, at 4:20 p.m.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ZBIO